Non-Cystic Fibrosis Bronchiectasis (NCFB) Market Size, Epidemiology, Trends, and Forecast 2025-2035

 The 7 major non-cystic fibrosis bronchiectasis (NCFB) markets reached a value of USD 1,661.7 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 6,901.9 Million by 2035, exhibiting a growth rate (CAGR) of 13.78% during 2025-2035.



NCFB is a progressive lung disease where there is persistent airway dilatation that leads to mucus plugging, repeated infection, and inflammation. This would mean that unlike cystic fibrosis-associated bronchiectasis, none of the treatments available is approved explicitly for NCFB, giving rise to an appreciable unmet medical need. Significant progress was mapped out in 2024 when Insmed's brensocatib was shown effective in a Phase 3 trial. As a first-in-class dipeptidyl peptidase 1 (DPP1) inhibitor, it drastically reduced the number of pulmonary exacerbations in patients with NCFB. In light of the successful outcomes, Insmed had submitted a New Drug Application to the FDA, with a likely U.S. launch by mid-2025

Advances in diagnostic technologies are also redefining management of NCFB. High-resolution computed tomography (HRCT) enables visualization of subtle bronchial abnormalities, making earlier and more precise diagnoses possible. Molecular diagnostics such as polymerase chain reaction (PCR) and next-generation sequencing (NGS) permit identification of pathogens and antibiotic resistance patterns with accuracy. Artificial intelligence (AI) is also being used to improve imaging analysis, ensuring consistency and assisting with treatment planning. The current treatment approaches are symptom-oriented, targeting inhaled antibiotics, airway clearance therapy, and anti-inflammatory drugs. Smart inhalers and remote monitoring devices are on the horizon, enabling real-time analysis of respiratory metrics and tailored adjustments to therapy. Telemedicine platforms are also broadening access to specialized care, especially in remote areas.

Request for a sample of this report: https://www.imarcgroup.com/non-cystic-fibrosis-bronchiectasis-market/requestsample

Countries Covered

  • United States
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Japan
     

Analysis Covered Across Each Country

  • Historical, current, and future epidemiology scenario
  • Historical, current, and future performance of the non-cystic fibrosis bronchiectasis (NCFB) market
  • Historical, current, and future performance of various therapeutic categories in the market
  • Sales of various drugs across the non-cystic fibrosis bronchiectasis (NCFB) market
  • Reimbursement scenario in the market
  • In-market and pipeline drugs


Competitive Landscape

This report also provides a detailed analysis of the current non-cystic fibrosis bronchiectasis (NCFB) marketed drugs and late-stage pipeline drugs.

In-Market Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance

Ask the Analyst for Customization and Explore the Full Report with TOC:https://www.imarcgroup.com/request?type=report&id=22243&flag=A

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact US:

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145

Comments

Post a Comment

Popular posts from this blog

Cancer Pain Market Size, Epidemiology, Trends, and Forecast 2025

Image
  The   cancer pain market size   reached a value of USD 1,778.2 Million across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 2,625.8 Million by 2035, exhibiting a growth rate (CAGR) of 3.61% during 2025-2035. The year of 2025 may see the cancer pain market in a raging state, made dynamic from the rise in cancer cases, changing treatment strategies, and significant technological progress. Cancer pain afflicts approximately 53% of all individuals diagnosed with the disease and 64% of those who have the illness at the advanced stage, holding a central position in oncology care. With increasing global cancer incidence, the demand for effective and patient-friendly management of pain has never been higher. A major factor responsible for this expansion is the rising prevalence of cancer worldwide. As the population ages and lifestyle-related risk factors increase, more and more people are getting d...
Read more

Obstructive Sleep Apnea Market Size, Epidemiology, Trends, and Forecast

Image
The 7 major  obstructive sleep apnea markets size  reached a value of USD 794.9 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 4,066.7 Million by 2035, exhibiting a growth rate (CAGR) of 16.2% during 2025-2035. Increased global awareness, increasing incidence rates, and technological advancements are largely contributing to the growth of the OSA market in 2025. Sleep apnea refers to periodic arousals from sleep accompanied by cessation of breathing and is a common ailment affecting millions of people across the globe. With increasing awareness about associated health risks such as hypertension, cardiovascular diseases, and diabetes, the demand for diagnosis and treatment on time is rapidly increasing.  One of the leading causes of market growth is the increasing incidences of sleep apnea. In the name of modern lifestyles, with instances of poor sleep hygiene, sedentary behavior, and increased calorie intake, sleep apnea cases are surging a...
Read more

Inflammatory Bowel Disease Market Overview and Trends in 2025

Image
 The 7 major  inflammatory bowel disease markets  reached a value of USD 14.92 Billion in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 20.08 Billion by 2035, exhibiting a growth rate (CAGR) of 2.73% during 2025-2035. Demand surges in the IBD market as the worldwide burden of chronic gastrointestinal disorders continues to increase in 2025. Crohn’s disease and ulcerative colitis are the two most common types of IBD;  they are lifelong diseases characterized by inflammation of the gastrointestinal tract. Increased awareness of the diseases coupled with the development of diagnostic and therapeutic measures is accelerating market growth globally. The focus areas of the market in 2025 are associated with the growing burden of IBD, particularly in developed North American and European countries. But there is a notable increase in prevalence in portions of Asia and even some Latin American countries, which is likely a result of urban lifestyle, dietary h...
Read more